Study of Value of Dexamethasone Used in Ovulation Induction

Infertility, Female Clinical Trial

Official title:

A RCT Study of Value of Dexamethasone Used in Ovulation Induction

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03421041
• Other study ID #: LCYJ-201801
• Status: Withdrawn
• Phase: N/A
• Start date: April 1, 2018
• Est. completion date: March 30, 2021

Study information

• Verified date: January 2021
• Source: Reproductive & Genetic Hospital of CITIC-Xiangya
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study intends to solve the following problems: whether use dexamethasone can obviously decrease transplant cancelling probability in fresh embryo transplant cycle or not, reduce time and frequency going to hospital repeatedly for patients need frozen embryo transplant or not, and reduce the economic burden for patients or not; By comparing pregnancy rate of single transplant, hope to make clear in IVF-ET treatment for patients progesterone increases to a certain level whether it is a good choice to transfer fresh embryo after dexamethasone treatment, or frozen embryo transplant is better.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 30, 2021
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• female, 18 years old=age=35 years old, 18=BMI=25, standard patient, menstrual regularity

Exclusion Criteria:

Hyperprolactinemia, Thyroid dysfunction, uterine malformation ( inadequacy mediastinal uterus =1.0cm, Unicornate uterus, double uterus, T Angle of uterus, etc.), uterus adhesion, untreated hydrosalpinx , hysteromyoma( hysteromyoma=1.0 cm, and/or endometrial hysteromyoma=1 cm), endometriosis, diabetes, hypertension, adrenal cortex hyperplasia, Cushing's syndrome, a pituitary amenorrhea

Related Conditions & MeSH terms

• Infertility
• Infertility, Female

Intervention

Drug:
• Dexamethasone Oral Tablet
Dexamethasone Oral Tablet,0.75mg/tablet

Locations

Country	Name	City	State
China	Reproductive & Genetic Hospital of CITIC-XIANGYA	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Reproductive & Genetic Hospital of CITIC-Xiangya

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cumulative pregnancy rate per oocyte retrieval cycle	cumulative pregnancy rate per oocyte retrieval cycle	Until 28 day after embryo transferred